LY4395089

Phase 2Small molecule

Eli Lilly

LY4395089 is one of 54 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Crohn DiseaseRecruiting

Colitis, UlcerativeRecruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Crohn DiseasePhase 2

Recruiting

Colitis, UlcerativePhase 2

Recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Omvoh

Eli Lilly

Phase 3

14 2

Velsipity

Pfizer

Phase 3

11 3

Mesalazine

Ferring

Phase 3

17 4

Adtralza

LEO Pharma

Phase 3

1 5

Deltavit

HHyundai Pharmaceutical Co., LTD.

JNJ-42756493

Simponi

15 8

Remicade

OOrganon and Co

Preclinical

26 9

Humira

CCelltrion

Preclinical

19 10

HMPL-004

HHutchison Medipharma Limited

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Colitis, Ulcerative

NCT07483073

Phase 2Recruiting

Crohn Disease

NCT07483099

Clinical

Trials by Indication[1]

Colitis, Ulcerative1 trial

A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07483073·60 enrolled

Crohn Disease1 trial

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07483099·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LY4395089. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4395089 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4395089. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY4395089

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Colitis, Ulcerative1 trial

Crohn Disease1 trial

References

Drug Info

Quick Facts

Related News